ASPIRIN

US Approved OTC

First marketed in 1899

Details

Stereochemistry	ACHIRAL
Molecular Formula	C9H8O4
Molecular Weight	180.1574
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(=O)OC1=C(C=CC=C1)C(O)=O

InChI

InChIKey=BSYNRYMUTXBXSQ-UHFFFAOYSA-N

InChI=1S/C9H8O4/c1-6(10)13-8-5-3-2-4-7(8)9(11)12/h2-5H,1H3,(H,11,12)

HIDE SMILES / InChI

Molecular Formula	C9H8O4
Molecular Weight	180.1574
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/011483s029lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/11723249

Aspirin is a nonsteroidal anti-inflammatory drug. Aspirin is unique in this class of drugs because it irreversibly inhibits both COX-1 and COX-2 activity by acetylating a serine residue (Ser529 and Ser516, respectively) positioned in the arachidonic acid-binding channel, thus inhibiting the synthesis of prostaglandins and reducing the inflammatory response. The drug is used either alone or in combination with other compounds for the treatment of pain, headache, as well as for reducing the risk of stroke and heart attacks in patients with brain ischemia and cardiovascular diseases.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Prostaglandin G/H synthase 1 30 Target ID: P23219\|\|\|Q5T7T7 Gene ID: 5742.0 Gene Symbol: PTGS1 Target Organism: Homo sapiens (Human) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/200671s000lbl.pdf	Inhibitor 8146		1.2 µM [IC50]
Prostaglandin G/H synthase 2 47 Target ID: P35354 Gene ID: 5743.0 Gene Symbol: PTGS2 Target Organism: Homo sapiens (Human) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/011483s029lbl.pdf	Inhibitor 8146		5.2 µM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Pain 607 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/011483s029lbl.pdf	Primary	Approved 8307	SYNALGOS-DC Approved Use SYNALGOS-DC is a combination of dihydrocodeine, an opioid agonist, aspirin, a nonsteroidal anti-inflammatory drug, and caffeine, a methylxanthine, and is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Launch Date -3.62620813E11
Headache 47 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a00c6776-e9ef-411b-9396-915c3787559a	Primary	Approved 8307	FIORINAL Approved Use FIORINAL is indicated for the relief of the symptom complex of tension (or muscle contraction) headache. Evidence supporting the efficacy and safety of Fiorinal in the treatment of multiple recurrent headaches is unavailable. Caution in this regard is required because butalbital is habit-forming and potentially abusable. Launch Date 2.00016003E11
Myocardial infarction 103 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/200671s000lbl.pdf	Preventing	Approved 8307	DURLAZA Approved Use DURLAZA is a nonsteroidal anti-inflammatory drug indicated to reduce the risk of death and myocardial infarction (MI) in patients with chronic coronary artery disease, such as patients with a history of MI or unstable angina pectoris or with chronic stable angina and to reduce the risk of death and recurrent stroke in patients who have had an ischemic stroke or transient ischemic attack. Launch Date 1.44132486E12
Stroke 143 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20884_AGGRENOX_prntlbl.pdf	Preventing	Approved 8307	AGGRENOX Approved Use AGGRENOX is indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis. Launch Date 9.4322878E11

C_max

Value	Dose	Co-administered	Analyte	Population
54.25 mg/L EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/24672263	500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered:		ASPIRIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
4.84 mg/L EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/24672263	500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered:		ASPIRIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
10.31 mg × h/L EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/24672263	500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered:		ASPIRIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
5.12 mg × h/L EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/24672263	500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered:		ASPIRIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
0.322 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/24672263	500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered:		ASPIRIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
0.422 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/24672263	500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered:		ASPIRIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
68% REVIEW https://www.ncbi.nlm.nih.gov/pubmed/30115648			ASPIRIN plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1670 inducer 753	substrate 985	substrate 1168 inducer 97

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
OAT3 625	CYP1A2 1013 CYP2A6 510 CYP2B6 648 CYP2C8 670 CYP2C19 955 CYP2E1 633 esterase 68 UGT1A1 417 UGT1A3 421 UGT1A6 306 UGT1A7 235 UGT1A8 282 UGT1A9 378 UGT1A10 289 UGT2B4 248 UGT2B7 387 P-gp 1491	CYP2C19 283 CYP1A2 671 CYP2E1 121 ABCA1 18 P-gp 252

Drug as perpetrator

Target	Modality	Activity
CYP1A2 1620	inducer 1515 Sources: https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1067/mcp.2003.14 Page: -	no
CYP2D6 1826	inducer 1515 Sources: https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1067/mcp.2003.14 Page: -	no
CYP2E1 929	inducer 1515 Sources: https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1067/mcp.2003.14 Page: -	no
ABCA1 18	inducer 1515 Sources: https://www.karger.com/Article/Abstract/321727 Page: -	yes
CYP2C19 1484	inducer 1515 Sources: https://www.sciencedirect.com/science/article/pii/S0928098715001153 Page: -	yes
CYP3A4 1857	inducer 1515 Sources: https://www.sciencedirect.com/science/article/pii/S0928098715001153 Page: -	yes
OAT3 627	inhibitor 3185 Sources: https://dmd.aspetjournals.org/content/42/6/996.short Page: -	yes
P-gp 1588	inducer 1515 Sources: https://pubmed.ncbi.nlm.nih.gov/11205285/ Page: -	yes

Drug as victim

Target	Modality	Activity	Metabolite
CYP1A2 1013	substrate 3264 Sources: https://www.sciencedirect.com/science/article/pii/S0928098715001153 Page: -	no
CYP1A2 1013	substrate 3264 Sources: https://www.sciencedirect.com/science/article/pii/S0928098715001153 Page: -	no	salicylic acid 18
CYP2A6 510	substrate 3264 Sources: https://www.sciencedirect.com/science/article/pii/S0928098715001153 Page: -	no
CYP2B6 648	substrate 3264 Sources: https://www.sciencedirect.com/science/article/pii/S0928098715001153 Page: -	no
CYP2B6 648	substrate 3264 Sources: https://www.sciencedirect.com/science/article/pii/S0928098715001153 Page: -	no	salicylic acid 18
CYP2C19 955	substrate 3264 Sources: https://www.sciencedirect.com/science/article/pii/S0928098715001153 Page: -	no
CYP2C8 670	substrate 3264 Sources: https://www.sciencedirect.com/science/article/pii/S0928098715001153 Page: -	no
CYP2C9 985	substrate 3264 Sources: https://www.sciencedirect.com/science/article/pii/S0928098715001153 Page: -	no
CYP2D6 1168	substrate 3264 Sources: https://www.sciencedirect.com/science/article/pii/S0928098715001153 Page: -	no
CYP3A4 1670	substrate 3264 Sources: https://www.sciencedirect.com/science/article/pii/S0928098715001153 Page: -	no
P-gp 1491	substrate 3264 Sources: https://www.tandfonline.com/doi/full/10.1080/00498254.2020.1757785 Page: -	no
UGT1A8 282	substrate 3264 Sources: https://dmd.aspetjournals.org/content/34/2/199.short Page: -	no	salicylic acid 18
UGT2B4 248	substrate 3264 Sources: https://dmd.aspetjournals.org/content/34/2/199.short Page: -	no	salicylic acid 18
UGT2B7 387	substrate 3264 Sources: https://dmd.aspetjournals.org/content/34/2/199.short Page: -	yes [Km 1242 uM]	salicylic acid 18
UGT1A3 421	substrate 3264 Sources: https://dmd.aspetjournals.org/content/34/2/199.short Page: -	yes [Km 2337 uM]	salicylic acid 18
UGT1A7 235	substrate 3264 Sources: https://dmd.aspetjournals.org/content/34/2/199.short Page: -	yes [Km 278.6 uM]	salicylic acid 18
UGT1A6 306	substrate 3264 Sources: https://dmd.aspetjournals.org/content/34/2/199.short Page: -	yes [Km 40.7 uM]	salicylic acid 18
UGT1A1 417	substrate 3264 Sources: https://dmd.aspetjournals.org/content/34/2/199.short Page: -	yes [Km 683.1 uM]	salicylic acid 18
UGT1A10 289	substrate 3264 Sources: https://dmd.aspetjournals.org/content/34/2/199.short Page: -	yes [Km 698.2 uM]	salicylic acid 18
UGT1A9 378	substrate 3264 Sources: https://dmd.aspetjournals.org/content/34/2/199.short Page: -	yes [Km 94.2 uM]	salicylic acid 18
CYP2A6 510	substrate 3264 Sources: https://www.sciencedirect.com/science/article/pii/S0928098715001153 Page: -	yes	salicylic acid 18
CYP2C19 955	substrate 3264 Sources: https://www.sciencedirect.com/science/article/pii/S0928098715001153 Page: -	yes	salicylic acid 18
CYP2C8 670	substrate 3264 Sources: https://www.sciencedirect.com/science/article/pii/S0928098715001153 Page: -	yes	salicylic acid 18
CYP2C9 985	substrate 3264 Sources: https://www.sciencedirect.com/science/article/pii/S0928098715001153 Page: -	yes	salicylic acid 18
CYP2D6 1168	substrate 3264 Sources: https://www.sciencedirect.com/science/article/pii/S0928098715001153 Page: -	yes	salicylic acid 18
CYP2E1 633	substrate 3264 Sources: https://www.sciencedirect.com/science/article/pii/S0928098715001153 Page: -	yes	salicylic acid 18
CYP3A4 1670	substrate 3264 Sources: https://www.sciencedirect.com/science/article/pii/S0928098715001153 Page: -	yes	salicylic acid 18
esterase 68	substrate 3264 Sources: https://www.sciencedirect.com/science/article/pii/S0928098715001153 Page: -	yes

Sourcing

Vendor/Aggregator	ID	URL
3B Scientific (Wuhan) Corp	3B1-00059	http://www.3bsc.com/index/pro_info.php?id=20271
AA Blocks	AA00I8UA	http://www.aablocks.com/goods/Goods/detail?id=AA00I8UA
AK Scientific, Inc. (AKSCI)	H740	http://www.aksci.com/item_detail.php?cat=H740
Aaron Chemicals	AR00I9M2	http://www.aaronchem.com/50-78-2
AbMole Bioscience	M5426	http://www.abmole.com/products/aspirin.html
Acadechem	ACDS-070196	http://www.acadechemical.com/product/144895
Achemica	ACMC-209kpz	http://www.achemica.com/prodinfo/?id=128318
Achemo Scientific Limited	AC-24217	http://www.achemo.com/search/?Keyword=50-78-2
Achemtek	0104-001327	http://www.achemtek.com/50-78-2
Acros Organics	AC158180500	https://www.fishersci.com/shop/products/acetylsalicylic-acid-99-acros-organics-1/AC158180500
Acros Organics	AC158185000	https://www.fishersci.com/shop/products/acetylsalicylic-acid-99-acros-organics-1/AC158185000
Acros Organics	AC158180025	https://www.fishersci.com/shop/products/acetylsalicylic-acid-99-acros-organics/AC158180025
Alfa Aesar	A12488	https://www.alfa.com/en/catalog/A12488/
Ambinter	Amb17757514	http://www.ambinter.com/reference/17757514
Angene	AGN-PC-0WACEM	http://www.angenechemical.com/productshow/AGN-PC-0WACEM.html
Anward	ANW-31125	http://www.anward.com/pro_result/20981
ApexBio Technology	A4013	http://www.apexbt.com/aspirin-acetylsalicylic-acid.html
Aurora Fine Chemicals LLC	A00.156.463	http://online.aurorafinechemicals.com/info?ID=A00.156.463
Aurora Fine Chemicals LLC	K00.801.915	http://online.aurorafinechemicals.com/info?ID=K00.801.915
Avantor Inc	TCA2262-25G	https://us.vwr.com/store/product/9983116/o-acetylsalicylic-acid-98-0-by-gc-titration-analysis
BOC Sciences	1173022-25-7	https://isotope.bocsci.com/product/acetylsalicylic-acid-13c-cas-1173022-25-7-343874.html
BOC Sciences	97781-16-3	https://www.bocsci.com/2-acetoxybenzoic-3-4-5-6-d4-acid-cas-97781-16-3-item-212339.html
BOC Sciences	921943-73-9	https://www.bocsci.com/acetylsalicylic-acid-d3-cas-921943-73-9-item-466862.html
BioChemPartner	BCP21790	http://www.biochempartner.com/50-78-2-BCP21790
BioCrick	BCC2097	http://www.biocrick.com/Aspirin-Acetylsalicylic-acid-BCC2097.html
Boerchem	BC221833	http://www.boerchem.com/?product_37473.html
Capot Chemical	20190	http://www.capotchem.com/en/20190.htm
Capot Chemical	PubChem20190	http://www.capotchem.com/en/20190.htm
Chem Scene	CS-2001	http://www.chemscene.com/50-78-2.html
ChemMol	49417180	http://www.chemmol.com/chemmol/49417180.html
ChemMol	99097732	http://www.chemmol.com/chemmol/99097732.html
Chemspace	CSSB00000210466	https://chem-space.com/CSSB00000210466
Clearsynth	CS-EG-00025	https://www.clearsynth.com/en/CSEG00025.html
Clearsynth	CS-ER-02340	https://www.clearsynth.com/en/CSER02340.html
Clearsynth	CS-T-01103	https://www.clearsynth.com/en/CST01103.html
Clearsynth	CS-T-47333	https://www.clearsynth.com/en/CST47333.html
DC Chemicals	DC8956	http://www.dcchemicals.com/product_show-Acetylsalicylic_acid.html
Debye Scientific	DS-017139	http://www.debyesci.com/cas_59096-14-9.html
Enamine	Z234893989	https://www.enaminestore.com/catalog/Z234893989
Finetech	FT-0655181	http://www.finetechnology-ind.com/prod/detail/pub/50-78-2.html
Finetech	FT-0661360	http://www.finetechnology-ind.com/prod/detail/pub/97781-16-3.html
Glentham Life Sciences	GL0865	http://www.glentham.com/products/product/GL0865/
Hairui	HR138909	http://www.hairuichem.com/en/product/50-78-2.html
LGC Standards	DRE-C10024000	https://www.lgcstandards.com/US/en/p/DRE-C10024000
LGC Standards	LGCAMP0133.00-11	https://www.lgcstandards.com/US/en/p/LGCAMP0133.00-11
LGC Standards	LGCFOR0133.00	https://www.lgcstandards.com/US/en/p/LGCFOR0133.00
LGC Standards	MM0133.00-0250	https://www.lgcstandards.com/US/en/p/MM0133.00-0250
Lab Network	LN00223310	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00223310
Matrix Scientific	134531	https://www.matrixscientific.com/134531.html
MedChem Express	HY-14654	https://www.medchemexpress.com/aspirin.html
MuseChem	A000653	https://www.musechem.com/product/A000653.html
Oakwood	101923	http://www.oakwoodchemical.com/ProductsList.aspx?CategoryID=-2&txtSearch=130521&ExtHyperLink=1
Parchem	30462	http://www.parchem.com/chemical-supplier-distributor/Aspirin-USP-2080B--020462.aspx
Parchem	12326	http://www.parchem.com/chemical-supplier-distributor/Aspirin-USP-26-002326.aspx
Parchem	30461	http://www.parchem.com/chemical-supplier-distributor/Aspirin-USP-3080--020461.aspx
Selleck Chemicals	S3017	http://www.selleckchem.com/products/aspirin-acetylsalicylic-acid.html
Sigma-Aldrich	239631_ALDRICH	https://www.sigmaaldrich.com/catalog/product/aldrich/239631?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	A0200000_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/a0200000?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	A2093_SIGMA	https://www.sigmaaldrich.com/catalog/product/sigma/a2093?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	A3160_SIGMA	https://www.sigmaaldrich.com/catalog/product/sigma/a3160?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	1044006_USP	https://www.sigmaaldrich.com/catalog/product/usp/1044006?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sinfoo Biotech	S054539	http://www.sinfoobiotech.com/product/1057937
Smolecule	S519564	http://www.smolecule.com/products/s519564
Synthetic Heterocycles	AFA100669	http://www.synhet.com/products/AFA100669
TCI (Tokyo Chemical Industry)	A2262	http://www.tcichemicals.com/eshop/en/us/commodity/A2262/index.html
THE BioTek	bt-260267	https://www.thebiotek.com/product/inhibitors/bt-260267
Tocris	4092	https://www.tocris.com/products/aspirin_4092
Vitas-M Laboratory	BBL005469	http://www.request.vitasmlab.biz/index.php?option=com_search_stk&Itemid=22&stk=BBL005469&?utm_source=pubchem&utm_medium=p_search_link&utm_campaign=pubchem_search&utm_content=pubchem_slink
VladaChem	VL271248-100G	https://www.vladachem.com/product.php?products=50-78-2
Yuhao Chemical	RT12808	http://www.chemyuhao.com/50-78-2.html
abcr GmbH	AB113303	http://www.abcr.com/shop/en/AB113303
eNovation Chemicals	D408997	http://www.enovationchem.com/productDetails.asp?productID=D408997
iChemical	EBD47326	http://www.ichemical.com/products/50-78-2.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
mcule	MCULE-3199019536	https://mcule.com/MCULE-3199019536/

PubMed

Title	Date	PubMed
Acetyl salicylic acid improves somatosensory evoked potentials in streptozotocin-diabetic rats.	1999 Dec	10624784
[Salicylism and glaucoma: reciprocal augmentation of the toxicity of acetazolamide and acetylsalicylic acid].	1999 Feb	10221197
Statins and peripheral neuropathy.	1999 Jan	10027656
Bleeding during warfarin and aspirin therapy in patients with atrial fibrillation: the AFASAK 2 study. Atrial Fibrillation Aspirin and Anticoagulation.	1999 Jun 28	10386508
Sulindac inhibits activation of the NF-kappaB pathway.	1999 Sep 17	10480951
Leukotriene receptor antagonists may prevent NSAID-induced exacerbations in patients with chronic urticaria.	2000 Aug	10982225
[Cholestatic hepatitis as a rare side effect of therapy with ticlopidine].	2000 Jul	10965556
Acetaminophen inhibits iNOS gene expression in RAW 264.7 macrophages: differential regulation of NF-kappaB by acetaminophen and salicylates.	2000 Jun 16	10860828
Aspirin-associated intracerebral hemorrhage: clinical and radiologic features.	2000 Jun 27	10881256
Cardiac risk factors, medication, and recurrent clinical events after acute coronary disease; a prospective cohort study.	2001 Feb	11161949
A novel synthetic inhibitor of factor Xa decreases early reocclusion and improves 24-h patency after coronary fibrinolysis in dogs.	2001 Feb	11160645
Heterogenous nature of flow-mediated dilatation in human conduit arteries in vivo: relevance to endothelial dysfunction in hypercholesterolemia.	2001 Feb 2	11157665
Addition of hydrophilic and lipophilic compounds of biological relevance to the monoolein/water system. I. Phase behavior.	2001 Jan	11163344
Present treatment options for unstable angina and non-Q-wave myocardial infarction.	2001 Jan	11161130
Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves.	2001 Jan	11157651
Antithrombotic therapy in atrial fibrillation.	2001 Jan	11157649
The PlA polymorphism of glycoprotein IIIa functions as a modifier for the effect of estrogen on platelet aggregation.	2001 Jan	11151063
Prehospital management of rapid atrial fibrillation: recommendations for treatment protocols.	2001 Jan	11146008
Endogenous nitric oxide and prostaglandins synergistically counteract thromboembolism in arterioles but not in venules.	2001 Jan	11145949
Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs.	2001 Jan	11138826
Active-control trials: how would a new agent compare with placebo? A method illustrated with clopidogrel, aspirin, and placebo.	2001 Jan	11136483
Review article: the gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase-2, in humans.	2001 Jan	11136272
Salicylate and cocaine: interactive toxicity during chicken mid-embryogenesis.	2001 Jan 15	11163537
Authors' reply on aspirin for primary prevention.	2001 Jan 20	11159585
Pharmacological properties of a newly synthesized H(+)/K(+) ATPase inhibitor, 1-(2-methyl-4-methoxyphenyl)-4-.	2001 Jan 5	11137875
Drug Points: tachycardia associated with moxifloxacin.	2001 Jan 6	11141146

Patents

Sample Use Guides

In Vivo Use Guide

Severe pain: Initiate treatment with two capsules (1 capsule contains 16 mg dihydrocodeine bitartrate, 356.4 mg aspirin, and 30 mg caffeine) orally every 4 hours as needed for pain. Headache: One or 2 capsules (1 capsule contains 50 mg butalbital, 325 mg aspirin and 40 mg caffeine) every 4 hours. Total daily dose should not exceed 6 capsules. Prevention of stoke and heart attacks: the recommended dose is one capsule of aspirin (162.5 mg) once daily. Take the capsules with a full glass of water at the same time each day. Prevention of stroke (in combination with dipyridamole): the recommended dose is one capsule (200 mg dipyridamole and 25 mg aspirin) given orally twice daily.

Route of Administration: Enteral

In Vitro Use Guide

Human platelet-rich plasma was incubated with various aspirin concentrations (10, 20, 50, 100, 200, 300, 400, 500 uM) at 37C for up to 4.5 h. Platelet aggregation and thromboxane generation were measured. Inhibition of platelet aggregation and thromboxane formation by 10 uM aspirin was maximal by 90 min. There was progressive inhibition by 3 uM aspirin during incubation for 270 min. By the end of this time there was also significant inhibition by 1 uM aspirin.

Substance Class	Chemical Created by `admin` on `Fri Dec 16 16:52:25 UTC 2022` Edited by `admin` on `Fri Dec 16 16:52:25 UTC 2022`
Record UNII	R16CO5Y76E
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ASPIRIN

Common Name

English

ASPIRIN COMPONENT OF VICOPRIN

Common Name

English

CLOPIDOGREL/ACETYLSALICYLIC ACID COMPONENT ASPIRIN

Brand Name

English

DUOCOVER COMPONENT ASPIRIN

Brand Name

English

ASPIRIN COMPONENT OF MICRAININ

Common Name

English

ACETYL SALICYLATE

Systematic Name

English

ASPIRIN COMPONENT OF EQUAGESIC

Common Name

English

2-ACETYLOXYBENZOIC ACID

Systematic Name

English

ASPIRIN [ORANGE BOOK]

Common Name

English

ASPIRIN COMPONENT OF AGGRENOX

Common Name

English

BAY1019036

Code

English

INVAGESIC FORTE COMPONENT ASPIRIN

Common Name

English

DUOPLAVIN COMPONENT ASPIRIN

Brand Name

English

ASPIRIN [USP MONOGRAPH]

Common Name

English

ASA

Common Name

English

ASPIRIN COMPONENT OF LANORINAL

Common Name

English

ACETYLSALICYLIC ACID [EMA EPAR]

Common Name

English

NSC-27223

Code

English

AGGRENOX COMPONENT ASPIRIN

Common Name

English

CODOXY COMPONENT ASPIRIN

Common Name

English

MEASURIN

Brand Name

English

ASPIRIN COMPONENT OF ROXIPRIN

Common Name

English

ROXIPRIN COMPONENT ASPIRIN

Common Name

English

ACETYLSALICYLIC ACID [GREEN BOOK]

Common Name

English

ACETYLSALICYLIC ACID (WHO-IP)

Common Name

English

NORGESIC COMPONENT ASPIRIN

Common Name

English

ASPIRIN COMPONENT OF ROBAXISAL

Common Name

English

ASPIRIN [MART.]

Common Name

English

ASPIRIN COMPONENT OF YOSPRALA

Brand Name

English

ASPIRIN COMPONENT OF NORGESIC

Common Name

English

MEPRO-ASPIRIN COMPONENT ASPIRIN

Common Name

English

ASPIRIN COMPONENT OF CARISOPRODOL COMPOUND

Common Name

English

ASPIRIN [VANDF]

Common Name

English

ORPHENGESIC COMPONENT ASPIRIN

Common Name

English

ASPIRIN COMPONENT OF SOMA COMPOUND

Common Name

English

PRAVIGARD PAC COMPONENT ASPIRIN

Common Name

English

ASPIRIN COMPONENT OF AXOTAL

Common Name

English

DARVON COMPOUND COMPONENT ASPIRIN

Common Name

English

ACIDUM ACETYLSALICYLICUM (WHO-IP)

Common Name

English

AXOTAL COMPONENT ASPIRIN

Common Name

English

INVAGESIC COMPONENT ASPIRIN

Common Name

English

ASPIRIN COMPONENT OF EXCEDRIN

Common Name

English

ASPIRIN COMPONENT OF INVAGESIC

Common Name

English

MICRAININ COMPONENT ASPIRIN

Common Name

English

ASPIRIN COMPONENT OF TALWIN COMPOUND

Common Name

English

LANORINAL COMPONENT ASPIRIN

Common Name

English

ASPIRIN COMPONENT OF INVAGESIC FORTE

Common Name

English

SYNALGOS-DC COMPONENT ASPIRIN

Common Name

English

ASPIRIN [JAN]

Common Name

English

ASPIRIN COMPONENT OF MEPRO-ASPIRIN

Common Name

English

ASPIRIN [USP-RS]

Common Name

English

NSC-406186

Code

English

BENZOIC ACID, 2-(ACETYLOXY)-

Common Name

English

ASPIRIN COMPONENT OF PRAVIGARD PAC

Common Name

English

FIORINAL COMPONENT ASPIRIN

Common Name

English

ASPIRIN COMPONENT OF AZDONE

Common Name

English

ACIDUM ACETYLSALICYLICUM

Common Name

English

ASPIRIN COMPONENT OF SYNALGOS-DC

Common Name

English

ASPIRIN COMPONENT OF PERCODAN

Common Name

English

CARISOPRODOL COMPOUND COMPONENT ASPIRIN

Common Name

English

Salicylic acid acetate

Systematic Name

English

Q-GESIC COMPONENT ASPIRIN

Common Name

English

Acetylsalicylic acid [WHO-DD]

Common Name

English

PERCODAN-DEMI COMPONENT ASPIRIN

Common Name

English

VICOPRIN COMPONENT ASPIRIN

Common Name

English

ASPIRIN COMPONENT OF DUOPLAVIN

Brand Name

English

ASPIRIN COMPONENT OF DUOCOVER

Brand Name

English

AZDONE COMPONENT ASPIRIN

Common Name

English

ACETYLSALICYLIC ACID [EP MONOGRAPH]

Common Name

English

EXCEDRIN COMPONENT ASPIRIN

Common Name

English

SOMA COMPOUND COMPONENT ASPIRIN

Common Name

English

ASPIRIN COMPONENT OF ORPHENGESIC

Common Name

English

ACETYLSALICYLICUM ACIDUM [HPUS]

Common Name

English

ASPIRIN [HSDB]

Common Name

English

ROBAXISAL COMPONENT ASPIRIN

Common Name

English

ACETYLSALICYLIC ACID

Official Name

English

2-(ACETYLOXY)BENZOIC ACID

Systematic Name

English

EQUAGESIC COMPONENT ASPIRIN

Common Name

English

PERCODAN COMPONENT ASPIRIN

Common Name

English

ASPIRIN COMPONENT OF CODOXY

Common Name

English

ASPIRIN COMPONENT OF PERCODAN-DEMI

Common Name

English

ASPIRIN [MI]

Common Name

English

YOSPRALA COMPONENT ASPIRIN

Brand Name

English

ORPHENGESIC FORTE COMPONENT ASPIRIN

Common Name

English

ASPIRIN COMPONENT OF Q-GESIC

Common Name

English

ACETYLSALICYLICUM ACIDUM

Common Name

English

ASPIRIN COMPONENT OF FIORINAL

Common Name

English

ASPIRIN COMPONENT OF ORPHENGESIC FORTE

Common Name

English

ASPIRIN COMPONENT OF CLOPIDOGREL/ACETYLSALICYLIC ACID

Brand Name

English

ACETYLSALICYLIC ACID [INCI]

Common Name

English

DURLAZA

Brand Name

English

TALWIN COMPOUND COMPONENT ASPIRIN

Common Name

English

ASPIRIN COMPONENT OF DARVON COMPOUND

Common Name

English

Classification Tree Code System Code

WHO-ATC

C07FX02